Business Wire

QUECTEL-WIRELESS

14.3.2023 09:02:03 CET | Business Wire | Press release

Share
Quectel Certification Services offering speeds up time to market and takes away certification cost and complexities for IoT devices

Quectel Wireless Solutions, a global IoT solutions provider, today announces Quectel Certification Services, its range of IoT device certification and testing services that will enable customers to rapidly certify their IoT devices with regulatory organisations such as the FCC, IC, CE, ANATEL, RCM, KC, Jate and Telec and carrier organisations including AT&T, Verizon, T-Mobile, Rogers, TELUS and Vodafone. This service will enable customers’ devices to gain certifications in under eight weeks and is not only the fastest time to market for IoT device manufacturers, but also the industry’s most cost-effective offering.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230314005140/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Quectel Certification Services offering speeds up time to market and takes away certification cost and complexities for IoT devices (Photo: Business Wire)

Certification across these disciplines is complex to achieve, involves multiple layers of certification from disparate organisations and, typically, local and regional authorities award certifications for device deployments in their own territories. The Quectel Certification Services span regulatory, conformance and carrier compliance requirements plus certifications for industry-specific devices and environmental and safety-related certifications, such as such as ATmosphere EXplosible (ATEX), Restriction of Hazardous Substances (RoHS), Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) and waste electrical and electronic equipment (WEEE).

“Going directly to certification or carrier organizations can result in it taking up to six months for IoT devices to gain certifications,” said Yoon Seungryoul, North American Certification Director, Quectel Wireless Solutions. “For many IoT use cases a six-month delay to launch is unacceptable and could make or break a proposition in markets where being first-to-launch is a critical differentiator. This is why Quectel, with our Quectel Certification Services, is bringing to customers our existing knowledge of certification and testing processes and our relationships with authorities, certification bodies, regulators, and carriers to provide our customers with the industry’s fastest and most cost-effective go-to-market offering.”

To further help customers, Quectel Certification Services offers a pre-scan service in its own labs so certification compliance can be assessed before applying to certification authorities, thereby saving time on non-compliant certification applications. A further benefit for customers that utilize both Quectel modules and antennas in their design, is that device testing is included for free. Quectel also offers technical support facilities and debugging solutions to address common, and not so common, certification issues.

Quectel’s capabilities include project management, administration, lab and carrier communications and management, checking and managing test scope, providing the necessary on-site support, and providing testing and debugging. In addition, Quectel will fix issues as they arise and negotiate waivers where appropriate.

“We’re proud to have launched Quectel Certification Services and we’re ready to provide full, global certification consultation and service to integrated device customers that have products that are based on Quectel modules,” added Seungryoul. “Quectel Certification Services have been gaining certifications for Quectel’s own modules and customers’ devices for many years, so we’re delighted to be bringing this expertise to customers and helping them accelerate time-to-market and build a smarter world.”

About Quectel

Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of over 4,000 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules, antennas and IoT connectivity.

With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.

For more information: www.quectel.com, LinkedIn, Facebook, and Twitter.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005140/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Together AI and HUMAIN Form Strategic Partnership to Accelerate AI Infrastructure and Cloud Services in Saudi Arabia31.8.2026 14:00:00 CEST | Press release

The partnership, which was announced on stage at LEAP, Combines HUMAIN’s AI Infrastructure Foundation with Together’s AI Native Cloud Platform and Global Reach Together AI, a leading San Francisco-based AI Native Cloud platform, and HUMAIN, a PIF company delivering full-stack artificial intelligence capabilities globally, today at LEAP announced a strategic partnership to connect HUMAIN’s rapidly expanding AI compute capacity in Saudi Arabia with global AI-native and enterprise demand. The partnership will include the construction of a new 250 megawatt data center, located in Saudi Arabia. The partnership brings together HUMAIN’s large-scale, multi-chip AI infrastructure footprint, expanding cloud and inference capabilities with Together AI’s global customer ecosystem and AI-native inference platform. Together, the companies will offer an additional option for developers, enterprises, and AI-native organizations worldwide to access high-performance AI infrastructure for inference and t

SLB to Acquire Kelvion, Expanding its Role Across Data Center Infrastructure31.8.2026 12:50:00 CEST | Press release

Scalable, energy-efficient and reliable thermal management technologies will optimize operating performance in increasingly complex data centers and industrial systems SLB (NYSE: SLB) today announced it has signed an agreement to acquire Kelvion, a global provider of thermal management and heat exchange technologies. The acquisition strengthens SLB's Data Center Solutions business with critical thermal management technologies and expands the company's role in data center infrastructure, which is one of the world’s fastest-growing industrial and technology markets. “AI is driving the most significant infrastructure investment cycle in our lifetime,” said Olivier Le Peuch, chief executive officer of SLB. “This transaction accelerates our ambition to become an industrial technology partner to the data center industry and help customers address the growing infrastructure complexity required to scale AI. Kelvion advances our path toward more integrated data center infrastructure solutions,

BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer31.8.2026 12:00:00 CEST | Press release

Findings provide further evidence of overall survival benefit of TEVIMBRA plus ZIIHERA and chemotherapy regimen in HER2+ GEAZIIHERA plus chemotherapy demonstrated statistically significant overall survival benefit at second interim analysis of HERIZON-GEA-01 trial BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the second interim analysis (IA2) of the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), in combination with chemotherapy, with and without TEVIMBRA® (tislelizumab), as first-line treatment for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). At IA2, ZIIHERA plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared with trastuzumab plus chemotherapy, meeting the remaining primary endpoint analysis of the study. IA2 also provided longer follow-up data for the TEVIMBRA plus ZIIHERA

GigaDevice Strengthens EMEA and Southeast Asia Market Reach Through Strategic Partnership with Rutronik31.8.2026 09:00:00 CEST | Press release

GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, today announced a new strategic franchise partnership with Rutronik Elektronische Bauelemente GmbH, one of Europe’s leading broadline distributors of electronic components. The agreement covers EMEA and Southeast Asia, including India, and provides customers with broader access to GigaDevice’s comprehensive portfolio of microcontrollers, sensors, and power management solutions. The partnership further strengthens GigaDevice’s distribution network and local market presence across key regions. With its strong presence across Europe and growing coverage in Southeast Asia, Rutronik provides GigaDevice with an established channel supported by extensive market reach, technical expertise, and customer relationships. The collaboration will help expand access to GigaDevice’s embedded solutions across a broad range of applications and industries, including indus

Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release

–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye